sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks Trametinib

Trametinib

CAS No.:
871700-17-3
Catalog Number:
AG0035PD
Molecular Formula:
C26H23FIN5O4
Molecular Weight:
615.3948
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
25mg
95%
In Stock USA
United States
$103
- +
100mg
95%
In Stock USA
United States
$158
- +
1g
95%
In Stock USA
United States
$644
- +
Product Description
Catalog Number:
AG0035PD
Chemical Name:
Trametinib
CAS Number:
871700-17-3
Molecular Formula:
C26H23FIN5O4
Molecular Weight:
615.3948
MDL Number:
MFCD17215075
IUPAC Name:
N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide
InChI:
InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)
InChI Key:
LIRYPHYGHXZJBZ-UHFFFAOYSA-N
SMILES:
CC(=O)Nc1cccc(c1)n1c(=O)n(C2CC2)c(=O)c2c1c(C)c(=O)n(c2Nc1ccc(cc1F)I)C
UNII:
33E86K87QN
Properties
Complexity:
1090  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
615.078g/mol
Formal Charge:
0
Heavy Atom Count:
37  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
615.404g/mol
Monoisotopic Mass:
615.078g/mol
Rotatable Bond Count:
5  
Topological Polar Surface Area:
102A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.4  
Literature
Title Journal
Trametinib suppresses HIV-1 replication by interfering with the disassembly of human immunodeficiency virus type 1 capsid core. Biochemical and biophysical research communications 20180108
Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Nature 20160901
Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Molecular cancer therapeutics 20160601
Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PloS one 20140101
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters 20130801
Trametinib (GSK1120212) in the treatment of melanoma. Expert opinion on pharmacotherapy 20130401
MEK and the inhibitors: from bench to bedside. Journal of hematology & oncology 20130101
Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clinical cancer research : an official journal of the American Association for Cancer Research 20120815
Improved survival with MEK inhibition in BRAF-mutated melanoma. The New England journal of medicine 20120712
Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide. Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20120501
Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. International journal of oncology 20110701
Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the '2011 ASCO Gastrointestinal Cancers Symposium'. San Francisco, CA, USA. January 20-22, 2011. JOP : Journal of the pancreas 20110309
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research 20110301
Properties